Scientific Advisory Council
Dr. Phil Branton, PhD
Dr. Phil Branton obtained his PhD in 1972 at the Ontario Cancer Institute, University of Toronto.
Following post-doctoral studies at MIT, he became a professeur adjoint at the Université de Sherbrooke, Sherbrooke, Quebec, then moved in 1975 to the cancer research group at McMaster University in Hamilton, Ontario, where he ultimately became professor of pathology and the group's co-ordinator.
He moved to McGill University as chair of biochemistry (1990-2000), and in 1996 was named Gilman Cheney Professor. In 2000, he was named the first scientific director of the Institute of Cancer Research (ICR) of the Canadian Institutes of Health Research (CIHR).
His honours include being made a Fellow of the Royal Society of Canada in 2002 and in 2005 being awarded the R.M. Taylor Medal from the Canadian Cancer Society and the National Cancer Institute of Canada (NCIC). He is currently a visiting scientist with Cancer Research U.K.
He is co-founder of GeminX Biotechnologies Inc. and is known for basic research on adenoviruses, cell death, protein degradation and tumour suppressors.
Dr. David R. Parkinson, MD
Dr. Parkinson is the president and CEO of Nodality, a biotechnology company based in San Francisco, California which is focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision-making.
Until October 2007, Dr. Parkinson was senior vice-president, oncology research and development at Biogen Idec. At Biogen Idec he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he was vice-president, oncology development, at Amgen and vice-president, global clinical oncology development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix.
Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as chief of the investigational drug branch, then as acting associate director of the cancer therapy evaluation program. He has also held academic positions at the MD Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine.
Dr. Simon Sutcliffe, MD
Currently, in addition to serving as Board Chair for the Canadian Partnership Against Cancer, Dr Sutcliffe is President of the International Cancer Control Congress Association and Chairs the International Steering Committee for the International Cancer Control Congress; President of the International Network for Cancer Treatment and Research – Canada Branch; Board Chair of the Institute for Health Systems Sustainability; and Associate Scientist with the Genome Sciences Centre, BC Cancer Agency and an Adjunct Professor in the Faculty of Graduate Studies, University of British Columbia.
Dr Sutcliffe was a staff oncologist and member of the senior scientific staff of the Ontario Cancer Institute/Princess Margaret Hospital (OCI/PMH) 1982-1989, the Vice President Oncology Programs 1989-1993, Professor of Radiology, University of Toronto (1989-1996), and the President and CEO of OCI/PMH 1994-1996. Between 1996 and 2000, Dr Sutcliffe was Vice President at the BC Cancer Agency with responsibility for the Vancouver Cancer Centre, academic development in oncology with the University of British Columbia and leadership of the Provincial Tumour Groups. Dr Sutcliffe was appointed President and CEO of the BC Cancer Agency (October 2000 – March 2009).
In 2002, Dr Sutcliffe was appointed as Chair of the Governing Council of the Canadian Strategy for Cancer Control (Canada’s national cancer control plan). With federal government funding of $250 million over 5 years for the plan in 2006, the Canadian Partnership Against Cancer (CPAC) was established. Dr Sutcliffe was appointed Chair of the Board of CPAC in June 2009.
More info here Simon Sutcliffe - October 2010.pdf
Dr. Jerome Yates, MD, MPH
For the past seven years, Dr. Jerome Yates has been national vice-president for research for the American Cancer Society.
He is a former senior vice-president for population sciences and senior vice-president for clinical affairs at Roswell Park Cancer Institute in Buffalo, New York, where he served for 14 years.
He received his MD from the University of Illinois (Chicago) and his MPH from Harvard University. He was trained in medical oncology and is certified by the American College of Physician Executives.
Early in his oncology career, he conducted studies of patients undergoing aggressive treatment or bone marrow transplantation for acute leukemia at Roswell Park Cancer Institute in Buffalo, New York. The "7 & 3" induction therapy for Acute Myelocytic Leukemia (AML) was developed and published in the early seventies and became the standard therapy for more than two decades in the United States, and remains the standard for remission induction in many other parts of the world.
For the next phase of his career, he was a founder director of the cancer centre at the University of Vermont. His palliative care research led to the evaluation of the hospice demonstration projects funded by the U.S. health care finance administration (now known as the Center for Medicare and Medicaid Services (CMS). He served on the evaluation oversight committee convened by the Institute of Medicine to develop the basis for the subsequent hospice regulations.
As the National Cancer Institute's associate director for centers and community oncology, he led a team that developed the Community Clinical Oncology Program (CCOP). He also pushed for the evaluation of the CCOPs and other NCI programs aimed at enhancing co-operative group clinical and cancer control trials.
He has served on a variety of advisory committees for cancer centres in the U.S. and internationally (including the advisory committee on research for the Alberta Cancer Board). He has served on a variety of peer review committees and has approximately 100 peer-reviewed publications.
Back to Top